Key facts
- Elusys’s last known valuation is $55.0M (Jul 2001).
- It has raised $56.1M; the latest was PE Growth/Expansion in Mar 2026.
- Notable investors include LEONID.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Elusys
- ·The full record, as it builds
Funding rounds
No funding rounds for Elusys are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Elusys
Developer of antibody therapeutics designed to treat life-threatening infectious diseases. The company's therapeutics treat anthrax exposure following a natural or intentional release of anthrax spores and also treat biodefense, cancer, lupus nephritis, contagious diseases, and thrombosis, enabling patients to prevent inhaled anthrax.
- Sector
- Healthcare
- HQ
- Parsippany, NJ, United States
- Founded
- 1998
- Employees
- 27
- Website
- elusys.com/
- Ownership
- Privately Held (backing)
Elusys doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elusys shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elusys in its N-PORT filings yet. We sweep new filings monthly.